Table 1 Characteristics of included studies

1

Kamya, 2007 [39]

Single blind RCT

Rural health center, March, 2006–July, 2006

42 days

253

256

6 months–10 years

Loss to follow up

0

0

ETF

0

0

LCF

19

30

LPF

73

89

ACPR

117

89

Fever clearance at day 1

137

137

Fever clearance at day 2

66

72

Fever clearance at day 3

52

57

Parasite clearance at day 2

1

2

Parasite clearance at day 3

0

0

Gametocyte carriage at baseline

9

18

Gametocyte carriage day 1–14

5

2

Gametocyte carriage at day 15–28

0

5

Gametocyte carriage at day 29–41

4

11

Hgb at baseline mean (SD)

9.5 (1.8)

9.7 (1.9)

Hgb g/dL at day 42 mean (SD)^a

1.9 (1.8)

1.5 (1.8)

Vomiting

65

65

Diarrhea

25

19

Anorexia

90

91

Abdominal pain

19

20

Weakness/malaise

85

103

Cough

136

133

Coryza

127

121

Pruritus

14

22

SAE

4

2

2

Yeka, 2008 [40]

Single-blind RCT

Health center, August 2006–April 2007

42 days

234

227

6 months–10 years

Los to follow up

3

3

ETF

0

1

LCF

9

23

LPF

17

41

ACPR

186

131

Fever clearance at day 1

117

133

Fever clearance at day 2

44

37

Fever clearance at day 3

22

22

Parasite clearance at day 2

7

5

Parasite clearance at day 3

0

0

Gametocyte carriage at baseline

12

18

Gametocyte carriage day 1–14

4

1

Gametocyte carriage at day 15–28

1

7

Gametocyte carriage at day 29–41

4

13

Hgb at baseline mean (SD)

9.9 (2.1)

9.9 (1.8)

Hgb at day 42 mean (SD)^a

1.8 (1.8)

1.7 (2.0)

Vomiting

35

35

Diarrhea

26

23

Anorexia

47

49

Abdominal pain

17

24

Weakness/malaise

28

27

Cough

164

150

Coryza

159

150

Pruritus

8

3

SAE

5

2

3

Arinaitwe, 2009 [35]

Open-label RCT

Local antenatal clinics in Tororo, August 2007–July 2008

63 days

119

111

6 weeks–12 months

Other anti-malaria use

1

2

Loss to follow up

5

2

Complicated malaria at day 0

0

1

Recurrent malaria caused by non-falciparum species

0

1

ETF

0

0

LCF

13

45

LPF

26

64

ACPR

306

205

Fever clearance at day 1

138

163

Fever clearance at day 2

13

17

Fever clearance at day 3

9

12

Parasite clearance at day 2

12

22

Parasite clearance at day 3

1

0

Gametocyte carriage at baseline

30

26

Gametocyte carriage day 1–14

10

1

Gametocyte carriage at day 15–28

1

0

Hgb at baseline mean (SD)

9.9 (1.5)

9.8 (1.5)

Hgb at day 28 mean (SD)^a

0.6 (1.68)

0.6 (1.56)

Vomiting

23

20

Diarrhea

79

86

Anorexia

3

0

Weakness

1

0

Cough

177

153

Pruritus

0

0

SAE

3

1

4

Bassat, 2009 [76]

Open-label RCT (non-inferiority)

Rural sites and one peri-urban site, August 2005–July 2006

42 days

164

82

6–59 months

PCR-corrected

ACPR day 28

155

77

PCR-corrected

ACPCR day 42

154

77

5

Katrak, 2009 [42]

Open-label RCT

N/A, August, 2007–April, 2008

N/A

124

122

6 weeks–12 months

Vomiting

19

9

Diarrhea

64

76

Cough

200

164

SAE

3

2

6

4ABC, 2011 [36]

Open-label RCT

N/A, July 2007–June 2009

63 days

422

421

6–59 months

Day 28 PCR-unadjusted ACPR

360

313

Day 28 PCR-adjusted ACPR

407

393

Day 63 PCR-unadjusted ACPR

234

209

Day 63 PCR-adjusted ACPR

375

371

7

Yeka, 2013 [37]

Single-blind RCT

Health center, December, 2007–April, 2009

28 days

72

35

6–59 months

LTF

0

0

ETF

0

0

LCF

6

7

LPF

12

14

ACPR

54

14

Fever clearance at day 1

48

14

Fever clearance at day 2

15

21

Fever clearance at day 3

4

2

Parasite clearance at day 2

2

5

Parasite clearance at day 3

0

0

Gametocyte carriage at baseline

0

0

Gametocyte carriage day 1–14

0

0

Gametocyte carriage at day 15–28

0

0

Hgb at baseline mean (SD)

10.8 (1.34)

10.6 (1.41)

Hgb at day 28 mean (SD)^a

0.8 (1.7)

0.9 (1.7)

Vomiting

3

2

Diarrhea

1

2

Anorexia

12

3

Abdominal pain

5

0

Weakness/malaise

1

0

Cough

47

20

SAE

0

0

8

Kakuru, 2014 [77]

RCT

District Hospital, August 2007 and April 2008

N/A

21

22

6 weeks–12 months

Loss to follow up

2

2

ETF

0

0

LCF

3

19

LPF

11

53

ACPR

149

127

Fever clearance at day 1

46

106

Fever clearance at day 2

7

16

Fever clearance at day 3

5

3

Parasite clearance at day 2

5

32

Parasite clearance at day 3

1

3

Gametocyte carriage at baseline

15

9

Gametocyte carriage at day 15–28

30

15

Hgb at baseline mean (SD)

9.6 (1.5)

10.1 (1.4)

Hgb at day 28 mean (SD)^a

1.0 (1.4)

0.6 (1.5)

Vomiting

8

18

Diarrhea

27

23

Anorexia

6

4

Weakness/malaise

2

2

Cough

64

74

9

Muhindo, 2014 [30]

Open-label, RCT

October District Hospital, October 2011–December, 2012

28 days

106

96

6 weeks–12 months

16

Loss to follow up

13

ETF

1

0

LCF

7

74

LPF

22

137

ACPR

311

189

Fever clearance at day 1

65

124

Fever clearance at day 2

11

8

Fever clearance at day 3

7

7

Parasite clearance at day 1

181

269

Parasite clearance at day 2

20

23

Parasite clearance at day 3

1

0

Hgb at baseline mean (SD)

11.2 (1.5)

11.1 (1.5)

10

Wanzira, 2014 [38]

Open-label, RCT

District Hospital, February 2009–2012

28 days

154

158

4 weeks–12 months

Other anti-malaria use

3

5

Loss to follow up

21

19

Withdrawn consent

1

2

ETF

2

15

LCF

48

475

LPF

182

894

ACPR

2403

1494

11

Yeka, 2019 [41]

Single-blind RCT

Health center and Hospital, October 2015–December, 2016

42 days

299

300

6–59 months

No outcome

11

10

ETF

0

0

LCF

32

50

LPF

43

85

ACPR

213

155

Fever clearance at day 1

208

231

Fever clearance at day 2

71

72

Fever clearance at day 3

31

18

Parasite clearance at day 1

219

245

Parasite clearance at day 2

22

34

Parasite clearance at day 3

3

3

Gametocyte carriage at baseline

59

60

Gametocyte carriage at day 1–42

43

46

Hgb at day 42 mean (SD)^a

1.3 (1.69)

0.8 (1.8)

Vomiting

56

61

Diarrhea

155

114

Anorexia

12

3

Abdominal pain

41

45

Headaches

18

24

Weakness/malaise

42

33

Cough

233

203

Pallor

22

13

Skin rash

56

42

Pruritus

24

16

SAE

6

6